December 5, 2019
Novartis to work on transformational treatment options
Today Novartis holds an investor event in London to provide a comprehensive overview of the its progress in advancing its industry-leading R&D pipeline.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
November 28, 2019
ValiRx gets a US patent for its anticancer therapeutic compound, sees it as validation of its potential anti-cancer impact
ValiRx got patent from the US Patent and Trademark Office for modulators Of the SRC-kinase activity for preventing or treating…
November 27, 2019
HIkma responds to FDA about GSK’s Advair Diskus
Hikma has submitted to the US Food and Drug Administration (FDA) its response to deficiencies in its abbreviated new drug application (ANDA) for a generic version of GlaxoSmithKline’s Advair Diskus® (fluticasone propionate and salmeterol inhalation powder).
November 16, 2019
Bristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
NEW YORK–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today that it currently expects there will be no further extension…
November 11, 2019
Mereo BioPharma’s phase two study of setrusubab misses primary goal
Mereo BioPharma Group’s Phase 2b dose-ranging “Asteroid” clinical study of setrusumab (BPS-804), an anti-sclerostin antibody, in adults with Type I,…
November 7, 2019
Scynexis confident in ibrexafungerp’s regulatory and commercial success
Scynexis biotechnology company on Thursday announced positive top-line results for its Phase 3 VANISH-303 study investigating the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC).
November 7, 2019
HLS Therapeutics expects Vatespa to transform business
HLS Therapeutics posted $1.9 million net loss in the third quarter 2019, compared to the same period last year, when it was compared to net loss of $19.7 million, boosted by Canadian-based clozaril sales in the last day of Q2.
November 7, 2019
Entrome, MSK to work on gut microbiome-derived antigens
Entrome SA, a clinical-stage biopharmaceutical company will work with Memorial Sloan Kettering Cancer Center (MSK) in New York City to evaluate the potential of gut microbiome-derived antigens for development as cancer immunotherapies.
November 6, 2019
Sandoz bags FDA’s approval for long-acting oncology supportive care biosimilar Ziextenzo
Sandoz Tuesday said it got approval from US Food and Drug Administration for its biosimilar Ziextenzo, which is in particularly significant since Sandoz short-acting filgrastim Zarxio is the first biosimilar to surpass its reference biologic in US market share.
November 6, 2019
4D pharma, Merck get confirmation for its Keytruda MRx0518 combo study
4D pharma Wednesday said that its clinical study with Merck to test MRx0518 combined with Keytruda further support its continued investment into our oncology franchise.